Early Blood Pressure Management in Extremely Premature Infants (ELGAN BP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This trial tests the feasibility of enrolling 60 extremely preterm infants in a randomized, double-blinded study of blood pressure management within 12 months. Eligible infants will receive an infusion drug (dopamine or a dextrose placebo) and a syringe drug (hydrocortisone or a normal saline placebo).
Enrolled infants will be randomized to receive one of the following drug pairs:
- dopamine and hydrocortisone
- dopamine and normal saline
- dextrose and hydrocortisone
- dextrose and normal saline.
In addition to the intervention above, the NRN is conducting a 6-month time-limited prospective observational study of all infants born at an NRN center between 23 and 26 weeks gestational age. All clinical decisions made for these babies will be at the discretion of the attending neonatologist/infant care team according to standard practice at each institution. Data on blood pressure management in the first 24 postnatal hours collected for each infant.
| Condition | Intervention |
|---|---|
|
Infant, Newborn Infant, Low Birth Weight Infant, Small for Gestational Age Infant, Premature Hypotension Blood Pressure |
Drug: Dopamine Drug: Hydrocortisone Drug: Infusion Placebo Drug: Syringe Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Early Blood Pressure Management in Extremely Preterm Infants Feasibility Pilot Study |
- Enrollment and completion of 60 infants [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Death [ Time Frame: 1 week and prior to hospital discharge ] [ Designated as safety issue: Yes ]
- Duration of antihypotensive therapy [ Time Frame: First 96 postnatal hours ] [ Designated as safety issue: Yes ]
- Receipt and timing of medical and/or surgical therapy for a PDA [ Time Frame: To hospital discharge ] [ Designated as safety issue: Yes ]
- Use of open-label antihypotensive therapies (inotropes, corticosteroids, blood and plasma volume expanders) for persistently low BP with biochemical evidence of poor perfusion [ Time Frame: First 96 postnatal hours ] [ Designated as safety issue: Yes ]
- Spontaneous gastrointestinal perforation [ Time Frame: First 7 days ] [ Designated as safety issue: Yes ]
- In-hospital complications (grade III or IV intraventricular hemorrhage, cystic periventricular leukomalacia, necrotizing enterocolitis requiring surgical intervention, retinopathy of prematurity requiring laser surgery, or bronchopulmonary dysplasia) [ Time Frame: To hospital discharge ] [ Designated as safety issue: Yes ]
| Enrollment: | 10 |
| Study Start Date: | July 2009 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Dopamine and hydrocortisone
Dopamine AND hydrocortisone
|
Drug: Dopamine
Dopamine
Drug: Hydrocortisone
Hydrocortisone
|
|
Active Comparator: Dopamine and placebo
Dopamine AND normal saline placebo
|
Drug: Dopamine
Dopamine
Drug: Syringe Placebo
Normal saline
|
|
Active Comparator: Placebo and hydrocortisone
Dextrose (D5W) placebo AND hydrocortisone
|
Drug: Hydrocortisone
Hydrocortisone
Drug: Infusion Placebo
Dextrose (D5W)
|
|
Placebo Comparator: Placebo and Placebo
Dextrose (D5W) placebo AND normal saline placebo
|
Drug: Infusion Placebo
Dextrose (D5W)
Drug: Syringe Placebo
Normal saline
|
Detailed Description:
Since most extremely preterm infants are critically ill in the immediate postnatal period, establishing "normal" blood pressure (BP) values is difficult. This lack of data makes deciding when to institute therapy for hypotension (low BP) challenging, leading to considerable variability in BP management in neonatal intensive care units (NICUs). Despite a lack of data on safety or efficacy, as many as 64% of extremely preterm infants receive inotropes (e.g., dopamine), and up to 12.4% of very low birthweight infants receive hydrocortisone for perceived hypotension. Since both untreated low BP and therapy provided for low BP may be harmful, the decision of whether to treat is an important issue. To date, no prospective randomized, controlled trial of BP management in this population has been performed.
This trial tests the feasibility of enrolling up to 60 extremely preterm infants in a randomized, double-blinded study of blood pressure management within 12 months. It will enroll 60 infants between 23 0/7 and 26 6/7 weeks gestational age born at 6 participating NICHD Neonatal Research Network sites. Eligible infants will receive a study infusion drug (dopamine or a dextrose placebo) and a study syringe drug (hydrocortisone or a normal saline placebo). Infants will be randomized to receive one of the following drug pairs: (1) dopamine and hydrocortisone; (2) dopamine and a placebo (normal saline solution); (3) a placebo (dextrose) and hydrocortisone; or (4) placebo (dextrose) and placebo (normal saline). (NOTE: dopamine is normally mixed with dextrose and hydrocortisone is mixed with saline solution before being administered, which is why two different placebos are being used in this trial.)
The information gathered will provide a framework for the design of a potential larger, multi-centered, randomized control trial.
NOTE: The NICHD Neonatal Research Network has received a FDA exemption from the IND regulations for this trial.
In addition to the interventional trial above, the NRN is conducting a 6-month time-limited prospective observational study of all infants born at an NRN center between 23 and 26 weeks gestational age. All clinical decisions made for these babies will be at the discretion of the attending neonatologist/infant care team according to standard practice at each institution. Data on blood pressure management in the first 24 postnatal hours collected for each infant.
Based on slow rate of recruitment, a time-limited observational study of hypotension in ELBW infants has been added to the current study.
Eligibility| Ages Eligible for Study: | up to 24 Hours |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Inborn infants
- 23 0/7 to 26 6/7 weeks estimated gestational age
- Umbilical arterial catheter in place at study entry
- <= 24 hours of age
Exclusion Criteria:
- Terminally ill infants
- Infants that have received (prior to enrollment): >20 ml/kg in fluid boluses, indomethacin, or ibuprofen
- Infants with major congenital anomalies
Contacts and Locations| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35233 | |
| United States, California | |
| Stanford University | |
| Palo Alto, California, United States, 94304 | |
| United States, Connecticut | |
| Yale University | |
| New Haven, Connecticut, United States, 06504 | |
| United States, Georgia | |
| Emory University | |
| Atlanta, Georgia, United States, 30303 | |
| United States, Indiana | |
| Indiana University | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Iowa | |
| University of Iowa | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Massachusetts | |
| Tufts Medical Center | |
| Boston, Massachusetts, United States, 02111 | |
| United States, Michigan | |
| Wayne State University | |
| Detroit, Michigan, United States, 48201 | |
| United States, New Mexico | |
| University of New Mexico | |
| Albuquerque, New Mexico, United States, 87131 | |
| United States, North Carolina | |
| Duke University | |
| Durham, North Carolina, United States, 27710 | |
| RTI International | |
| Durham, North Carolina, United States, 27705 | |
| United States, Ohio | |
| Cincinnati Children's Medical Center | |
| Cincinnati, Ohio, United States, 45267 | |
| Case Western Reserve University | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Rhode Island | |
| Brown University, Women & Infants Hospital of Rhode Island | |
| Providence, Rhode Island, United States, 02905 | |
| United States, Texas | |
| University of Texas Southwestern Medical Center at Dallas | |
| Dallas, Texas, United States, 75235 | |
| University of Texas Health Science Center at Houston | |
| Houston, Texas, United States, 77030 | |
| United States, Utah | |
| University of Utah | |
| Salt Lake City, Utah, United States, 84108 | |
| Principal Investigator: | Beau J. Batton, MD | Case Western Reserve University, Rainbow Babies and Children's Hospital |
| Principal Investigator: | Ronald N. Goldberg, MD | Duke University |
| Principal Investigator: | Krisa P. Van Meurs, MD | Stanford University |
| Principal Investigator: | Waldemar A Carlo, MD | University of Alabama at Birmingham |
| Principal Investigator: | Kristi L. Watterberg, MD | University of New Mexico |
| Principal Investigator: | Roger G. Faix, MD | University of Utah |
| Principal Investigator: | Abhik Das, PhD | RTI International |
| Principal Investigator: | Edward F. Bell, MD | University of Iowa |
| Principal Investigator: | Abbot R. Laptook, MD | Brown University |
| Principal Investigator: | Barbara J. Stoll, MD | Emory University |
| Principal Investigator: | Brenda P. Poindexter, MD MS | Indiana University |
| Principal Investigator: | Kurt Schibler, MD | Cincinnati Children's Medical Center |
| Principal Investigator: | Kathleen A. Kennedy, MD MPH | The University of Texas Health Science Center, Houston |
| Principal Investigator: | Pablo J. Sanchez, MD | University of Texas |
| Principal Investigator: | Seetha Shankaran, MD | Wayne State University |
| Principal Investigator: | Richard A. Ehrenkranz, MD | Yale University |
| Principal Investigator: | Ivan D. Franz III, MD | Tufts University |
More Information
Additional Information:
Publications:
| Responsible Party: | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| ClinicalTrials.gov Identifier: | NCT00874393 History of Changes |
| Other Study ID Numbers: | NICHD-NRN-0041, U10HD021364, U10HD027880, U10HD034216, U10HD036790, U10HD040492, U10HD053089, U10HD053124, UL1RR025744, UL1RR025764, UL1RR025777, M01RR000064, M01RR000070, U10HD027904, U10HD027853, U10HD040689, U10HD027851, UL1RR025008, U10HD021373, U10HD027856, U10HD053109, UL1RR024979, U10HD053119, UL1RR025747, U10HD021385, U10HD027871, UL1RR024139 |
| Study First Received: | April 1, 2009 |
| Last Updated: | April 30, 2013 |
| Health Authority: | United States: Federal Government United States: Institutional Review Board |
Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
|
NICHD Neonatal Research Network Very Low Birth Weight (VLBW) Extremely Low Birth Weight (ELBW) Prematurity |
Blood Pressure Management Dopamine Hydrocortisone |
Additional relevant MeSH terms:
|
Birth Weight Hypotension Body Weight Signs and Symptoms Vascular Diseases Cardiovascular Diseases Dopamine Dopamine Agents Cortisol succinate Hydrocortisone acetate Hydrocortisone 17-butyrate 21-propionate Hydrocortisone Hydrocortisone-17-butyrate |
Cardiotonic Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Anti-Inflammatory Agents Dermatologic Agents |
ClinicalTrials.gov processed this record on May 19, 2013